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Abstract: The recognition of the synovial tissue, as the primary target of inflammation in RA, has driven research in this 
field, not only to clarify the disease pathogenesis but also to evaluate local changes in response to treatment. Special 
interest has been given to the identification of sensitive synovial biomarkers that could be of help in demonstrating proof 
of principle in early stages of drug development. Synovial sublining macrophages have been shown to correlate with 
scores for disease activity in cross-sectional studies. Moreover, decreased disease activity as measured by the disease 
activity score evaluated in 28 joints (DAS28) after effective treatment, has consistently been associated with a reduction 
of the number of CD68+ synovial sublining macrophages across different therapies. This observation highlights a possible 
final common pathway in the mechanism of action of various therapies and supports the notion that macrophages have a 
central role in RA pathogenesis. 
When considering experimental therapies, the study of serial synovial biopsies in relatively small numbers of patients, in 
the context of proof of principle trials, successfully distinguished between effective and ineffective treatments. This 
attractive approach can be used during early drug development for screening proposes, supporting which new treatments 
have higher probability to be beneficial in a large scale clinical trial. 
In this paper we review the effects of RA treatments on the synovial tissue, including targeted therapies, with particular 
attention to their effect on synovial biomarkers. 
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1. INTRODUCTION 
  The aim of rheumatoid arthritis (RA) treatment is to 
reduce synovial inflammation and prevent joint destruction. 
The introduction of conventional disease-modifying 
antirheumatic drugs (DMARDs) and corticosteroids in RA 
management has been developed without a full 
understanding of their mechanisms of action. Specific 
targeted therapies have been introduced based on the 
increased knowledge of RA pathogenesis, highlighting a 
translation from serendipity to a selective interference with 
inflammatory and immune pathways. 
  Although a systemic disease, the hallmark of RA is 
chronic synovitis that affects multiple joints and invades 
cartilage causing bone erosions. Therefore, special interest 
has been given to the study of synovial tissue, not only to 
clarify the disease pathogenesis but also to evaluate local 
changes in response to treatment. First, such studies may 
provide insight into the mechanisms of action of a 
therapeutic intervention. Another goal of analysing synovial 
tissue is to identify molecular biomarkers that could be of 
help to predict response to treatment in individual patients. 
The ideal synovial biomarker would be able to discriminate  
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at baseline between responders and non-responders to 
treatment, possibly leading to a more efficient and 
personalized treatment. Finally, the analysis of serial 
synovial biopsies is particularly attractive when analysing 
potential new therapies on the group level in proof of 
principle trials. As the main therapeutic target, changes in the 
synovial membrane can be used to detect early effects of 
treatment. 
  In this paper we review the effect of treatments on the 
features of the synovium in vivo. The in vitro and ex vivo 
experiments using different synovial cell lineages and tissue 
samples cultured in vitro will not be discussed, since they are 
beyond the scope of this article. 
2. CORTICOSTEROIDS 
  The discovery of corticosteroids, more than 50 years ago, 
represents a remarkable progress in the treatment of 
inflammatory arthritis. Their anti-inflammatory effects are 
well known, including the impairment of pro-inflammatory 
cytokine synthesis and lymphocyte function as well as their 
adhesion to endothelial cells [1]. During the last decade, the 
mechanism of action of corticosteroids on the synovial tissue 
has been analysed, with compelling results. 
  In a randomized, double-blinded, placebo-controlled 
trial, patients given oral prednisolone 60 mg/day for one 
week followed by 40 mg/day in the second week (COBRA 
schedule), exhibited a significant decrease in the number of 
CD68
+ macrophages, but also CD5
+ (B and T cells), CD4
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(subset of T cells) and CD163
+ (subset of resident 
macrophages) cells. An analysis of covariance model 
showed that for CD68+ sublining macrophages, the 
estimated effect of prednisolone was large. Patients receiving 
active treatment had markedly fewer macrophages after 
therapy compared with those receiving placebo. This study 
identified, from a large panel of synovial biomarkers, 
sublining macrophages as an optimal marker to evaluate 
clinical response to corticosteroids. Staining for cytokines 
showed a reduction of the expression of interleukin (IL)-1 
and tumor necrosis factor (TNF), which are mainly produced 
by macrophages, and there was also a trend towards a 
reduction of markers associated with neoangiogenesis, such 
as vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF) and v3 integrin [2]. For 
patients treated with the same PDN regimen, it has been 
shown that real time quantitative-polymerase chain reaction 
(qRT-PCR) might provide additional information regarding 
treatment efficacy in small proof of principle clinical trials 
[3]. Prednisolone markedly decreased IL-8 and matrix 
metalloproteinases-1 (MMP-1) mRNA expression compared 
with placebo, and the confidentially intervals excluded the 
likelihood of no effect. 
  Methylprednisolone pulses were also associated with a 
rapid (within 24 hours) and significant reduction of 
inflammatory cytokines such as TNF and IL-8, but not of IL-
1 or IL-1Ra. The adhesion molecules, E-selectin and inter-
cellular adhesion molecule 1 (ICAM-1), were decreased, 
suggesting that this could be a possible mechanism of 
inhibiting neutrophils migration into the synovium [4, 5]. 
  It has previously been demonstrated in randomized 
controlled trials that corticosteroids can improve 
radiographic progression [6]. In accordance with this clinical 
effect and the reduced MMP-1 mRNA expression after 
prednisone therapy, methylprednisolone pulses were able to 
reduce the expression of MMP-1 and of tissue inhibitor of 
metalloproteinases 1 (TIMP-1), possibly as a result of the 
reduction of the number of macrophages, albeit not reaching 
statistical significance at 24 hours. Of interest, there was no 
change in MMP3 expression, perhaps contributing to the 
relatively moderate effect of corticosteroids in preventing 
joint destruction [3, 7]. 
  Intra-articular (IA) corticosteroids injection is a possible 
therapeutic approach when one or a few joints are affected, 
sparing patients from the systemic toxicity of oral 
administration. The mechanism by which IA corticosteroids 
suppress inflammation in the synovial membrane and the 
reason for an unpredictable clinical response in daily practice 
is still not fully elucidated. Previous work has shown that IA 
corticosteroid treatment results in decreased synovial 
inflammation [8]. In all patients the local treatment resulted 
in a decreased arthritis activity of the treated knee joint as 
measured clinically or histologically. 
  In another study of thirteen patients, 6 of which had RA, 
the administration of 40 mg triancinolone hexacetonide IA 
was accompanied by a significant reduction of the synovial 
receptor activator for nuclear factor  B ligand  (RANKL) 
expression, while osteoprotegerin (OPG) expression 
remained unchanged [9].  
  S100A12 (calgranulin C), a member of the phagocytic 
S100 family of calcium-binding proteins that is expressed 
and secreted by activated granulocytes, has been proposed as 
a synovial biomarker of clinical response to IA 
corticosteroids and also to infliximab. S100A12 is expressed 
in patients with active RA and its serum concentrations 
correlate with synovial fluid levels and disease activity. In a 
group of 14 patients, successful treatment with IA 
corticosteroids led to a decrease of S100A12 sublining 
expression two weeks after injection in the responders group, 
the same happening with infliximab at 8 weeks [10]. 
3. CONVENTIONAL DISEASE-MODIFYING 
ANTIRHEUMATIC DRUGS 
  DMARDs are able to decrease joint inflammation and 
prevent radiographic damage. Conventional DMARD therapy 
has been introduced for the treatment of RA and other forms 
of inflammatory arthritis as an empirical approach to RA 
management. Therefore, only a few trials have analysed the 
effect of these treatments in the synovial membrane. 
  Gold has been used in the treatment of RA for more than 
60 years; however only a few studies looked at its effects on 
the synovium, with divergent results. In two studies, synovial 
T cells numbers were reduced after 6 months of gold treatment 
[11, 12]. Another study showed a decrease in CD68+ 
macrophage numbers as well as in the expression of 
macrophages-derived cytokines (TNF, IL-1 and IL-6), 
without changes in the number of T or B cells, 12 weeks after 
initiation of treatment with intramuscular gold or a 
combination of intramuscular gold with methylprednisolone 
[13]. 
  Methotrexate, the so called anchor-drug in the treatment of 
RA, was shown to be associated with a decrease in the number 
of macrophages, T and plasma cells at 16 weeks of successful 
therapy. Interestingly, corroborating the previously described 
effect of oral prednisolone, a trend towards an association 
between clinical improvement and the reduction of CD68
+ 
macrophages scores was depicted [14]. This relationship was 
confirmed when other DMARDs were included in the 
analysis, such as leflunomide, sulphasalazine, hydroxychloro-
quine and infliximab. The mean change in DAS28 (DAS28) 
consistently correlated with the mean change in sublining 
CD68+macrophages (CD68sl) suggesting that macrophages 
correlate with clinical improvement independently of the 
therapeutic strategy, probably reflecting a common final 
pathway regarding their mechanisms of action [15]. This 
correlation was confirmed in different centres indicating that 
the relationship between CD68+ macrophages and disease 
activity is reproducible across centres [16, 17]. The sensitivity 
to change of the number of CD68+ sublining macrophages 
was determined by calculation of the standardized response 
mean (SRM). After effective DMARDs treatment the SRM 
for this biomarker was high (>0.8) indicating high sensitivity 
to change while it was low when ineffective therapies (anti-
CCL2 or anti-C5aR) were analysed. Consistent with previous 
studies, CD68+ macrophages are less susceptible to placebo 
effects than clinical evaluation (DAS28) indicating a high 
sensitivity in discriminating between effective and ineffective 
therapies or placebo [18-20]. 
  Following DMARD treatment (mainly methotrexate and 
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(IL-1 and TNF) and adhesion molecules (E-selectin, ICAM-1 
and VCAM-1) has been described, particularly evident in the 
responder groups [14, 21, 22]. After 4 months of treatment 
with either methotrexate or leflunomide, the results were 
generally similar. Of importance, MMP-1 expression and the 
ratio MMP-1/TIMP-1 were also diminished after treatment. 
These changes were, again, more evident in the group that had 
achieved an ACR20 response [22]. In addition, successful 
treatment with DMARDs resulted in a reduction of RANKL 
and increase in OPG expression in the synovium. There was a 
significant correlation between RANKL, DAS28 and erosion 
scores, highlighting the benefits of DMARDs in improving 
radiographic outcomes [23]. The consistent relationship 
between clinical improvement, associated with protection 
against joint destruction, and decreased synovial inflammation 
after DMARD treatment, is in line with the observation that 
synovitis is a predictor of joint damage [24-26]. 
  Examination of serial synovial tissue samples may also 
provide insight into the mechanisms underlying the resistance 
to treatment. Loss of efficacy detected with the long-term use 
of some DMARDs is well known by clinicians but the reasons 
for this secondary failure are poorly understood. Cell 
membrane–associated drug efflux transporters belonging to 
the family of ATP-binding cassette (ABC) proteins have been 
associated with acquired resistance to anticancer drugs as well 
as DMARDs. In vitro methotrexate, leflunomide and 
sulphasalazine can be exported from cells via the breast cancer 
resistance protein (BCRP). BCRP was recently found to be 
expressed in macrophages in RA synovial tissue. After 4 
months of treatment with methotrexate or leflunomide, high 
BCRP expression was associated with persistence of 
infiltrating macrophages and higher DAS28 and C reactive 
protein (CRP) levels. Similarly, patients who did not respond 
to treatment had higher BCRP cell counts suggesting that 
BCRP might be responsible for the efflux of these drugs in 
macrophages, inducing resistance to therapy [27]. 
  Taken together, the results above reinforce the importance 
of macrophages in the pathogenesis of RA (reviewed in ref. 28 
and ref. 29) and suggest that the immunomodulatory action of 
DMARDs might be in part dependent on the down-regulation 
of cytokines and adhesion molecules with a consequent 
decrease of the inflammatory synovial cellular infiltrate [28, 
29]. These studies have also shown the efficacy of DMARDs 
in modulating the RANKL/OPG ratio and reducing MMP 
expression and consequently joint destruction (reviewed in ref. 
30) The number of synovial sublining macrophages has been 
demonstrated to be a reliable biomarker of therapeutic 
response to DMARDs in clinical trials [30]. 
4. BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC 
DRUGS 
4.1. Anti-TNF Therapy 
  Three TNF antagonists are at present widely used in 
clinical practice: infliximab, a chimeric monoclonal 
antibody, adalimumab, a fully monoclonal antibody and 
etanercept, a TNF-receptor Fc-fusion protein. As observed 
with conventional DMARDs, TNF antagonists clearly 
improve the signs and symptoms associated with synovial 
inflammation. Different mechanisms might contribute to 
their efficacy in decreasing the synovial infiltrating cells: the 
impairment of cell migration, cell proliferation and/or cell 
retention; the reduction of adhesions molecules, cytokines, 
chemokines and metalloproteinases expression; and the 
regulation of angiogenesis [31]. 
  Studies on the effect of TNF antagonists on synovial cells 
have demonstrated that cell infiltration is significantly 
reduced as early as 48 hours, two and four weeks after the 
first infliximab infusion [32-34]. 
  At 48 hours, the number of intimal CD68+ macrophages 
was significantly diminished and a trend towards a reduction 
of sublining CD68+ macrophages, T and plasma cells was 
also detected [32]. An enhancement of apoptosis and 
cytotoxicity, or an interference with cell trafficking have 
been proposed to explain the rapid reduction of synovial 
cellularity, but their exact role remains to be elucidated. 
  Synovial cell hyperplasia is a characteristic of pannus 
and resistance to apoptosis by fibroblast-like synoviocytes 
(FLS), T and B cells has been widely demonstrated [35, 36]. 
Of interest, using TUNEL assays, a sensitive method for 
detecting apoptosis induced DNA fragmentation, the number 
of TUNEL-positive cells in the infliximab treated group was 
similar to placebo at 48 hours and these results were 
confirmed by electron microscopy [32]. Similar findings 
were obtained at 1 and 24 hours after treatment, by active 
caspase 3 staining and other methods, making apoptosis 
induction as a mechanism underlying the reduction of 
synovial cellularity less likely [37]. 
  Reduced synovial cell counts after TNF antagonist 
treatment could perhaps be explained by modulation of cell 
migration. Synovial tissue is most certainly a dynamic tissue 
in which the number of infiltrating cells is dependent on the 
balance between their influx, proliferation and efflux [38]. 
The interaction between inflammatory and endothelial cells 
is of great importance and is probably mediated by a wide 
range of cytokines and chemokines. RA synovial tissue 
endothelial cells express high levels of E-selectin, VCAM-1, 
ICAM-1 and ICAM-3 and the last 3 have also been 
identified in other synovial cells including macrophages, 
FLS and lymphocytes [39]. The synovial expression of E-
selectin and VCAM-1 was shown to be decreased after 
infliximab treatment [34].
 A reduction of serum level of E-
selectin and ICAM-1 is associated with an increase of 
circulating lymphocytes early after TNF blockade, possible 
indicating reduced migration into the synovium [40]. In 
addition, the expression of IL-8 and monocytes chemotactic 
protein (MCP)-1 chemokines on synovial membrane is also 
down-regulated by anti-TNF therapy, suggesting that TNF 
antagonists might also act by diminishing chemokine-
mediated attraction of leucocytes [39]. These data are further 
supported by the evidence of impairment of neutrophil-
trafficking measured by labeled granulocytes gammagraphy 
after infliximab administration [33]. It is at present not clear 
if this endothelial deactivation is a direct effect of TNF 
blockade or whether it results from the decrease in 
macrophages numbers or expression of cytokines produced 
by the inflammatory cells. 
  Formation of new blood vessels is crucial for the 
maintenance of hyper-proliferative synovium, through 
nutrient supply and delivery of inflammatory cells and other 
inflammatory molecules. Pro-angiogenic factors including 
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factor (PDGF), tumor growing factor (TGF) , TNF, and 
chemokines such as IL-8 and Gro have been detected in 
synovial membrane [39]. However, the baseline expression 
of VEGF and bFGF, as well as of E-selectin, ICAM-1 and 
VCAM-1, were not predictive of response to infiliximab 
after 16 weeks of therapy [41]. 
  The TNF like weak inducer of apoptosis (TWEAK) has 
recently been implicated in inflammatory arthritis 
pathogenesis. Through the interaction with its receptor, the 
fibroblast growth factor inducible 14 (Fn14), TWEAK can 
drive FLS to produce cytokines and chemokines, promote 
bone destruction and develop pro-angiogenic effects. 
TWEAK and Fn14 are widely expressed in RA synovium, 
namely in the lining, sublining and perivascular regions, and 
their co-localization could be detected in FLS and 
macrophages. Interestingly, infliximab treatment did not 
modulate TWEAK and Fn14 expression, underlining the 
additional potential benefits of blocking their activation as a 
new therapeutic target [42]. 
  Anti-TNF therapy could finally contribute to the 
clearance of immune cells from the synovial membrane by 
increasing their traffic into the lymphatic draining system. 
Consistent with this hypothesis lymphatic vessels are 
abundantly present in patients with RA and their formation is 
increased after infliximab treatment [43]. 
  Despite the excellent response obtained by most of the 
patients after anti-TNF treatment, 40% do not respond to 
these therapies and some of the initial responders develop 
secondary failure [44, 45]. Baseline TNF expression has 
been found to be, at least in part, a determinant of the 
primary clinical response to infliximab, with responders 
exhibiting high levels of TNF in the lining and sublining 
comparing to non responders [41]. Positivity for lymphocyte 
aggregates further increased the power to predict the clinical 
response, when analyzed in a prediction model that included 
baseline disease activity, anti-cyclic citrullinated peptide 
antibody positivity, and synovial TNF expression [46]. 
Consistent with these results responders to anti-TNF therapy 
have higher expression levels of genes directly involved in 
inflammation in the synovial tissue, including those related 
to immunity and defence, T-cell mediated immunity, cell 
adhesion, cytokine and chemokine mediated signalling 
pathway, and macrophage-mediated immunity [47]. 
4.2. Rituximab 
  Rituximab, a chimeric monoclonal antibody against the B 
lymphocyte surface marker CD20, has been used in the 
treatment of RA for the last 7 years with encouraging results 
[48-50]. The recognition of its efficacy in controlling RA 
manifestations has driven research in this field aiming to 
explain the role of B cells in RA pathogenesis. Rituximab 
may cause circulating B cell depletion through antibody-
dependent cell-mediated cytotoxicity, complement-dependent 
cytotoxicity and apoptosis [51]. 
  The synovial B cell infiltrate in RA patients is very 
heterogeneous regarding the number of cells and its 
distribution. B cells might be found as a scarce or diffuse 
infiltrate, in follicles or integrated in germinal centers as 
those seen in the lymphoid tissues [52, 53]. The almost 
complete peripheral B cell depletion and the lack of 
correlation between the degree of depletion and clinical 
response raises the hypothesis of residual non depleted 
resident B cells in non-peripheral compartments, including 
lymphoid and synovial tissues [51]. Analysing the effect of 
rituximab on synovial cell populations, a significant decrease 
in the number CD22
+ B cells has been detected in some but 
not in all treated patients, 4 weeks after the first rituximab 
infusion. In addition, different patterns of depletion were 
observed, from a complete clearance of B cells to a partial 
decrease in synovial B cell number [54]. These results where 
further confirmed at 16 weeks post-treatment with a trend 
towards a more pronounced reduction of B cells in patients 
who had persistent B cell counts at 4 weeks. Moreover, a 
significant decrease in the number of T cells, macrophages 
and lymphoid aggregates was also depicted at the group 
level and a marked reduction of plasma cells in a subset of 
patients [55]. Other studies have addressed this same 
question. A complete depletion of CD20
+ cells at 12 weeks 
in 88% of patients after rituximab treatment has been 
identified but the concomitant use of prednisolone might 
have influenced these results [56]. Another study confirmed 
the variable reduction of synovial B cells after rituximab 
treatment [57]. 
  Taken together, these studies have shown marked B cell 
depletion in the peripheral blood, whereas synovial B-
lineage cells may persist in some patients. Local protective 
factors, such as B lymphocyte stimulator (BLyS) and CD55 
(decay-accelarating factor (DAF)), and more efficient B cell 
depletion in the peripheral compartment might explain these 
results [55]. The secondary decrease in macrophages and T 
cells highlight the role of B cells in orquestrating synovial 
inflammation and suggest that the clinical response to 
rituximab could be predicted by changes in synovial cell 
types other than B cells. 
  These studies have also analysed the correlation between 
changes in the synovial cell infiltrate, disease activity and 
response to treatment. Although the baseline characteristics 
of the synovium do not appear to predict the response to 
treatment, the secondary reduction of plasma cells and 
intimal macrophages between 4 and 16 weeks after initiation 
of rituximab treatment was associated with the clinical 
response at 24 weeks. Interestingly, the decrease in plasma 
cell numbers was also correlated with a reduction of serum 
anti-citrullinated protein antibodies (ACPA) levels at 16 
weeks.
 In addition, the decrease in circulating ACPAs could 
be related, at least in part, to changes in synovial short-lived 
plasma cells, derived from B cells and responsible for 
autoantibody production [55]. In line with these observations, 
other investigators found an association between persistence 
of synovial CD79a
+ CD20
- B-lineage cells, exhibiting plasma 
cell morphology, and disease activity after rituximab 
treatment [56, 58]. 
4.3. Abatacept 
  Abatacept, a human cytotoxic T-lymphocyte antigen 
(CTLA)-4 and Fc-IgG1 fusion protein that blocks the co-
stimulatory signal between CD28 and CD80/CD86, is 
approved for the treatment of active RA patients, refractory 
to MTX or to TNF antagonists. The only study that 
determined the effects of abatacept on the synovium, 
demonstrated a moderate, although statistically significant 
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failed TNF antagonists. The lack of reduction of T cell 
counts is probably consistent with a more 
immunomodulatory effect on T cell activation rather than a 
direct effect on cell depletion; binding of abatacept to 
CD80/CD86 on B cells should also be considered. In parallel 
to the mild changes in synovial cell infiltrate there was a 
marked decrease in pro-inflammatory gene expression in the 
synovial tissue, including interferon , IL-1, MMP-1 and 
MMP-3, which was also statistically significant when 
comparing responders to non responders [59]. 
5. EXPERIMENTAL TARGETED THERAPIES 
5.1. Complement Blockade 
5.1.1. C5a Blockade 
  Complement has been considered to be implicated in RA 
pathogenesis and recently it was shown that, in vitro, ACPA 
are able to activate complement [60]. Complement proteins 
and its receptors can be locally produced and activated in the 
RA synovial membrane [61]. 
  Different molecules that block the possible role of C5a in 
recruiting and activating synovial inflammatory cells have 
been developed. One of these is PMX53 (Promics Ltd), an 
orally active hexapeptide that selectively antagonizes CD88, 
the C5a receptor. A double-blind, placebo-controlled proof 
of principle phase 1b trial demonstrated no evidence of 
clinical efficacy. Consistently, PMX53 did not reduce the 
synovial inflammatory cell infiltrate (including C5aR+cells 
and macrophages) or the expression of inflammatory 
cytokines (IL-6, IL-1 and TNF) [62]. 
5.2. Chemokine Blockade 
  Chemokines are a group of chemotactic proteins that 
exhibit a similar basic structure. They are key mediators of 
cell migration but also stimulate cells to release 
inflammatory mediators and matrix metalloproteinases. 
Therefore, chemokines and chemokine receptors are thought 
to be key players in the inflammatory response observed in 
RA synovium. 
5.2.1. CCL2 Blockade 
  CCL2/ monocyte chemotactic protein (MCP)-1 is the 
ligand for CCR2 on monocytes, T cells, dendritic cells, 
basophils and natural killer cells. It is highly expressed in 
RA synovium where it is mainly produced by macrophages 
[63, 64].
 Based on the concept that blocking inflammatory 
cell migration into the synovial would improve arthritis in 
RA patients, the efficacy of a human monoclonal antibody 
directed against CCL2/MCP-1 (ABN912; Novartis Pharma 
AG) was tested [65]. ABN912 treatment was not associated 
with any clinical or immunohistologic improvement and in 
fact dose dependent increases in C-reactive protein 
concentrations, sublining macrophage numbers and 
CCL2/MCP-1 serum levels were detected. MLN202, an anti-
CCR2 antibody (Millenium Pharmaceuticals Inc.) was also 
evaluated in a proof of principle trial, but again no clinical or 
synovial improvement was identified, suggesting that using 
these compounds in larger clinical trials would not translate 
into any clinical benefit [66]. 
 
 
5.2.2. CCR1 Blockade 
  In RA patients the percentage of CCR1 and CCR5 
positive peripheral blood monocytes cells is decreased when 
comparing to healthy controls, but they are highly expressed 
in the synovial tissue [64]. The potential benefits of blocking 
CCR1, using CP 481,715 (Pfizer Inc.), an oral CCR1 
antagonist, were studied in a small-placebo controlled proof 
of principle trial. Two weeks after treatment there was a 
significant reduction of synovial macrophages and CCR1 
positive cells together with a trend towards clinical 
improvement as compared to placebo [67]. The use of 
another CCR1 antagonist, MLN3897, Millennium 
Pharmaceuticals Inc.), did not result in clinical improvement 
in RA [68]. Thus, it is at present unclear whether blockade of 
CCR1 at optimal levels of receptor occupancy might be 
sufficient to induce amelioration of RA. 
5.3. Cytokines 
5.3.1. IL-10 
  The systemic administration of human recombinant IL-
10 in active RA patients showed no improvement of cell 
infiltration or cytokine expression in accordance with a lack 
of clinical benefit [18]. 
5.3.2. Interferon  
  Evaluation of the effect of systemic treatment with 
interferon  (IFN ) on the synovial tissue from RA patients 
showed a modest reduction of CD3+ T cells, but no 
statistically significant change in CD68+ macrophages, in 11 
RA patients; this effect was lost 3 months after therapy [69]. 
Consistent with these results, a double-blind, placebo-
controlled clinical trial in 209 RA patients showed no 
improvement after treatment with either 2.2 mg or 44 mg of 
IFN, given subcutaneously three times weekly for 24 weeks 
compared to placebo [70]. It remains to be determined 
whether other dosing regimens or other routes of 
administration may be more effective. 
5.4. Targeting T Cells 
5.4.1. Alemtuzumab 
  Alemtuzumab (Campath-1H), a humanized antibody 
against CD52 that is broadly expressed on lymphocytes and 
macrophages, did not decrease synovial T cells in two 
patients with recurrent synovitis after treatment, despite 
inducing profound depletion of circulating lymphocytes 
(mainly CD4+ cells) [71]. The further evaluation of 
alemtuzumab for treatment of RA was discontinued due to 
anxieties related to prolonged therapy-induced lymphopenia. 
5.4.2. Anti-CD4 
  The chimeric anti-CD4 monoclonal antibody cM-T412, 
when administered intravenously, for five days, to 7 patients, 
significantly decreased the synovial T cells, the expression 
of adhesion molecules and peripheral CD4+ cells counts. 
There was however no statistically significant reduction of 
CD68+ macrophages and there was no clinical improvement 
[72]. The lack of efficacy was convincingly shown in a 
double-blind, placebo-controlled multicenter trial in 64 
patients receiving concomitant methotrexate [73]. 
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6. CONCLUSIONS 
  The synovium is the major target tissue in RA and other 
inflammatory arthritides. The evaluation of serial synovial 
biopsies has proven to be advantageous to improve 
knowledge regarding RA pathogenesis, new molecular 
targets and major mechanisms of action of RA therapeutics. 
In addition, CD68+ sublining macrophages have been 
recognized as a synovial biomarker that may help to 
distinguish on the group level between effective and 
ineffective treatment in an early stage of drug development. 
The correlation between sublining CD68+macrophages and 
disease activity as measured by DAS28 has consistently been 
shown across different therapies, suggesting a possible 
common final pathway in their mechanism of action. 
  Analyzing synovial samples in proof of principle trials 
was demonstrated to be helpful for screening proposes. The 
absence of significant changes in the number of CD68+ 
sublining macrophages after therapeutic interventions 
paralleled the lack of clinical benefit. This was for instance 
shown for systemic treatment with IL-10, IFN, a C5a 
receptor antagonist, anti-CD4 antibodies, anti-CCR2 
antibodies and anti-MCP-1 antibodies. The lack of 
correlation between changes in peripheral blood compared to 
synovial tissue highlight the importance of considering the 
inclusion of synovial biomarkers in clinical trials. The 
profound depletion of peripheral T and B cells after 
alemtuzumab or rituximab treatment, respectively, did not 
concur with the same profound changes in the synovial 
compartment. Collectively, these results clearly support the 
usefulness of examination of synovial biopsies in proof of 
principle trials. 
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